FDA Brief

Warning letters Food

FDA warning letter to

Native Remedies dba Silver Star Brands

High riskIssued Feb 18, 2021Posted Feb 19, 2021Center for Food Safety and Applied Nutrition (CFSAN)

FDA warned Native Remedies that MindSoothe Drops and Capsules are unapproved, misbranded drugs promoted for depression and sleep problems.

What happened

FDA reviewed nativeremedies.com in December 2020 and found the company takes orders there for MindSoothe Drops and MindSoothe Capsules. The website claims included relieving feelings of depression, regulating disturbed sleep patterns, improving disturbed appetite, and a testimonial saying MindSoothe helped depression. FDA said these claims show the products are intended as drugs, but they are not FDA-approved and lack adequate directions for use.

What FDA found

  1. The website's claims that MindSoothe treats depression, sleep problems, and appetite changes show the products are intended as drugs.

    FD&C Act § 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]
  2. The products are new drugs not generally recognized as safe and effective for those uses and were offered without FDA approval.

    FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]
  3. The products are misbranded because they lack adequate directions for use for conditions that require a licensed practitioner.

    FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]
  4. The company introduced or delivered misbranded drugs into interstate commerce.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to address the violations, explain how recurrence will be prevented, and include related documentation. If the company believes it is not in violation, it should include its reasoning and supporting information; if it cannot complete the work, it should state why and give a timeline.

Who should pay attention

  • companies selling supplements with disease-treatment claims
  • retailers and online marketplaces carrying MindSoothe or similar products
  • regulatory teams reviewing website claims and testimonials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk